CSL 112

Drug Profile

CSL 112

Alternative Names: Apolipoprotein A-I - CSL Behring; CSL-112; CSL112 (reconstituted HDL) - CSL; rHDL - CSL

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL
  • Class Antihyperlipidaemics; Cardiovascular therapies; Lipoproteins
  • Mechanism of Action Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atherosclerosis; Myocardial infarction

Most Recent Events

  • 26 Aug 2017 Pharmacodynamics and pharmacokinetics data from a phase II trial in Myocardial infarction presented at the Annual Congress of the European Society of Cardiology (ESC-2017)
  • 01 Jun 2017 CSL Behring completes a phase II trial for Myocardial infarction in USA, Hungary, Germany, Netherlands, Israel (IV) (NCT02742103)
  • 17 Mar 2017 Pharmacodynamics data from a phase I trial in Renal impairment presented at the 66th Annual Scientific Session of the American College of Cardiology (ACC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top